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Peroxisome proliferator-activated receptor gamma (PPARc) is a key regulator of adipocyte differentiation and has an important
role in metabolic syndrome. Phosphorylation of the receptor’s ligand-binding domain at serine 273 has been shown to change
the expression of a large number of genes implicated in obesity. The difference in gene expression seen when comparing wild-
type phosphorylated with mutant non-phosphorylated PPARc may have important consequences for the cellular molecular
network, the state of which can be shifted from the healthy to a stable diseased state. We found that a group of differentially
expressed genes are involved in bi-stable switches and form a core network, the state of which changes with disease
progression.These ﬁndings support the idea that bi-stable switches may be a mechanism for locking the core gene network into
a diseased state and for efﬁciently propagating perturbations to more distant regions of the network. A structural analysis of the
PPARc–RXRa dimer complex supports the hypothesis of a major structural change between the two states, and this may
represent an important mechanism leading to the differential expression observed in the core network.
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Regulatory and signaling pathways connecting constituent
parts of the cell (DNA, RNA, proteins and metabolites)
coordinate multiple cellular functions, which can be studied
using a network representation of physical molecular interac-
tions. Cell decision processes are dependent on the structure
and dynamics of, for example, gene-regulatory networks.
Different steady-stable states (also called attractor states)
appear to be related to distinct functional phenotypic states of
the cell.
1
Proteinsexistaspopulationsofstatesofdifferentstructures
and energies, including native structural states, malfunction-
ing and highly unfolded species. Biological function might be
altered by protein misfolding, impairment of protein-binding
events and malfunctioning of the allosteric control mechan-
ism. As transition between these states often requires
crossing high-energy barriers, penetration of the full energy
landscape under unperturbed conditions is low. However,
speciﬁc perturbations, such as mutations, changes in pH
and temperature, post-translational modiﬁcations and inter-
molecular binding, modify the protein energy landscape and
shift the protein population towards other conformations.
2,3
Malfunctioning proteins, for instance, have a role as the
infectious agent in prion disease.
4 Similar events are
hypothesized to occur in other protein misfolding diseases
such as Alzheimer’s, Huntington’s and Parkinson’s in which
protein agents may similarly induce pathological protein
states.
5,6 Protein population shift as a result of external stimuli
can be observed in the post-translational modiﬁcations of
crystallin protein leading to cataract formation
7 or the
misfolding of S100 proteins caused by changing metal ion
concentrations, which are implicated in cancer, neurodegen-
erative, inﬂammatory and autoimmune diseases.
8
The metabolic syndrome describes a cluster of metabolic
abnormalities encompassing elevated fasting glucose con-
centrations, increased waist circumference, increased trigly-
cerides, low HDL cholesterol levels and high blood pressure.
9
It occurs with a prevalence of 20–25% worldwide according to
the IDF (International Diabetes Federation),
10,11 and is on the
rise, especially in the elderly population, and more alarming
even in children and adolescents.
12
Total and cardiovascular mortality is increased in the
metabolic syndrome, and the risk of developing overt type II
diabetes is increased ﬁvefold.
13,14 From a pathophysiological
point of view, the metabolic syndrome is widely held to be
caused by central adiposity that can lead to insulin resistance
under given genetic and environmental circumstances.
15
Peroxisome proliferator-activated receptor gamma
(PPARg), a versatile member of the nuclear receptor
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cancer and other diseases. The disease outcome is asso-
ciated with PPARg gene polymorphism or mutation (Table 1).
PPARg is most abundantly expressed in the adipose tissue
and is of key importance in adipocyte differentiation and
triglyceride storage.
16 It also participates in glucose home-
ostasis and insulin sensitivity and thus, synthetic ligands for
PPARg, the so-called thiazolidinediones, have been devel-
oped and approved to treat type II diabetes. However, the
exact mechanism of action of these drugs is not yet fully
elucidated, primarily because these compounds bind to
PPARg not only in the adipose tissue. Moreover, it is still
unclear how PPARg controls the balance between obesity as
result of increased adipogenesis and insulin sensitivity.
Thiazolidinediones increase insulin sensitivity, but seemingly
paradoxically also cause weight gain.
17 Studies on naturally
occurring mutations in humans have not been conclusive;
some have shown increased PPARg transcriptional activity
with increased adipogenesis and obesity, whereas others
have demonstrated decreased transcriptional activation and
lower body mass and increased insulin sensitivity.
18,19
Recent work has shown that high-fat feeding of mice
activates protein kinase cyclin-dependent kinase 5 (CDK5) in
adipose tissues, leading to the phosphorylation of PPARg at
serine 273
20 (Figure 1). In in vitro experiments, CDK5-
mediated phosphorylation of serine 273 led to the differential
expression of a subset of genes, including a number of key
metabolic regulators, which were consistent with genes
differentially expressed in mice fed a high-fat diet.
20 This
ﬁnding suggests that phosphorylation alters the regulatory
functionofPPARg andmay beinvolved in thepathogenesisof
insulin resistance in humans. Comparison of wild-type
phosphorylated (putative disease state) with non-phosphory-
lated mutant (putative healthy state) cell lines reveals
signiﬁcant differences in the expression levels of genes,
which may have a role in disease development. Hundreds of
genes not expressed in the healthy state are upregulated
when PPARg is phosphorylated, leading to changes at the
cellular level.
In this study, we investigated how the phosphorylation of
serine 273 in PPARg shifts the protein population towards a
malfunctioning state and consequently perturbs cellular
molecular networks, eventually leading to the development
of insulin resistance. In a structural analysis of the PPARg–
retinoid X receptor alpha (RXRa) dimer complex, we
examined changes between the two states that may
constitute an important mechanism leading to the differential
expression observed in the network. We studied the effects
with a particular focus on the DNA-binding domain (DBD) of
Table 1 PPARg polymorphisms and mutations related to disease
Disease Variant dbSNP
a
Modiﬁer of obesity, insulin resistance Pro12Ala rs1805192
Obesity, severe Pro115Gln rs1800571
Lipodystrophy, familial partial, type 3 Cys190Ser rs121909245
Lipodystrophy, familial partial, type 3 Arg194Trp rs121909246
Colon cancer, somatic Gln314Pro rs121909242
Colon cancer, somatic Arg316His rs28936407
Colorectal cancer Ser317Cys –
Lipodystrophy, familial partial, type 3 Val318Met rs72551362
Colon cancer, somatic Lys347Ter rs121909243
Lipodystrophy, familial partial, type 3 Phe388Leu rs72551363
Lipodystrophy, familial partial, type 3 Arg425Cys rs72551364
Glioma susceptibility 1 His477His rs3856806
Lipodystrophy, familial partial, type 3 Pro495Leu rs121909244
aIdentiﬁer in dbSNP, http://www.ncbi.nlm.nih.gov/snp
Figure 1 PPARg transcriptional regulation. In the normal state (left) and in the metabolic syndrome leading to dyslipidemia (right)
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Cell Death and Diseasethe receptor, using molecular dynamic (MD) simulations.
PPARg and RXRa form a highly cooperative functional dimer.
Each monomer consists of a DBD and a ligand-binding
domain (LBD) linked by long hinge fragment. Dimerization
requires contacts between the LBD and the DBD of both
receptors, as well as interaction between PPARg’s LBD and
the ﬁrst segment of RXRa’s hinge. The binding of DNA and
ligands has a role in a complex stabilization process: by
binding to both receptors’ DBD, PPARg LBD stabilizes DNA
binding. The PPARg–RXRa heterodimer binds to a PPAR
response element (PPRE), which is composed of a direct
repeat separated by one or two base pairs (PPREs that have
one intervening base pair are often referred to as a direct
repeat 1 or DR1). The minor grove of the DR1 protects a small
polar DBD–DBD interface (PPARg Asn188 and RXRa Arg209
and Gln206), from the solvent what fortiﬁes inter-domain
interactions and hence stabilizes the protein–DNA complex.
21
Several disease-related polymorphisms and mutations
located in the LBD might affect stability of the LBD directly
(Phe388, Arg425, Pro495) or impair ligand binding (Gln314,
Arg316, Ser317, Val318 and His477; see Table 1). The
importanceofLBD–DBDdomaincooperationtoassemblethe
functional complex was demonstrated by mutating the highly
conserved Phe375 residue that led to weakened DNA
binding.
21 Serine 273 is possibly another example in which
LBD residue modiﬁcation may lead to altered DNA binding:
phosphorylation occurs on the interface between the LBD of
PPARg and the DBD of RXRa and therefore may change
RXRa-DNA binding.
Subsequently, we built a cell-speciﬁc network of molecular
interactions, including direct physical interactions and indirect
regulatory interactions, based on the comparison of the gene
expression patterns produced by wild-type phosphorylated
and mutated non-phosphorylated PPARg.
20 We analyzed the
dynamics of bi-stable motifs in healthy and diseased states,
theorizing that circuits exhibiting bi- and multi-stability may
drive network state transitions associated with disease
progression and then maintain networks in diseased states.
Such bi-stable switches are found, for example, in protein–
protein interaction or regulatory networks, allowing cells to
make irreversible decisions and assume different fates
depending on which genes are expressed or silent.
22 In the
networkunder study,thesemotifs shouldnot existin isolation,
but assemble an interconnected core cluster of genes that
regulate one another, ensuring the stability of the network. In
addition, differentially expressed genes (DEGs) belonging to
bi-stable switches should be central to the regulatory network,
so that they can efﬁciently propagate perturbations to more
distant regions of the network.
Results
Theeffects of the phosphorylation of serine 273 on the protein
structure of PPARg were studied by comparing the structures
of phosphorylated serine 273 and the wild type, with a
particularfocusontheDBDofthereceptorcomplex,usingMD
simulations. Although a detailed study on DBD dynamical
properties under perturbing stimuli and its relation to DR1-
binding speciﬁcity is not the subject of this paper, a simple
comparison of time-averaged molecular motions can indicate
regions of altered stability. Indeed, serine 273 phosphoryla-
tion affects the stability of RXRa,mostly in the zinc-ﬁnger helix
which is in contact with DNA’s major groove (Figure 2a). The
general change in the structure of DBD-RXRa is relatively
small: 0.5A ˚ of averaged atomic displacement (root-mean
S.D.) (Figure 2b). Nevertheless, the whole domain became
less stable, as shown in differences in the root mean square
ﬂuctuation proﬁles (Figure 2c), with the most remarkable
ﬂuctuation occurring in the helical region of one of the zinc
ﬁngers. This indicates that phosphorylation introduces
changes in the DNA-binding domain, shifting the protein
population towards a state which could contribute to an
increase in disease-related gene expression. The LBD of
PPARg is not affected on a large scale; despite some
differences, both proﬁles are following a similar trend
(Figure 2d).
To study the effects of modiﬁed PPARg gene regulation, we
reconstructed an interaction network consisting of 235 DEGs,
152 of which were upregulated in the phosphorylated state
(wild type) and 48 of which were upregulated in the mutated
state (S273A mutant). We call this network the ‘global’
network.
Subsequently, we searched a sub-network that makes
an important contribution to the stability of the global
network. First, we searched for motifs with multi-stable
modes. We then selected the top 10 statistically signiﬁcant
motif types consisting of 2, 3, 4 or 5 nodes using a z-value-
based ranking, all having a P-value o0.01 (only 10 of 1000
randomly generated networks contained motifs at a higher
frequency). We examined the expression proﬁle of the
genes in each motif to ensure that the expression proﬁle
was consistent in all members of the identiﬁed motif: among
the top ranked 2-, 3-, 4- or 5-node motifs that exhibited
multi-stable behavior, we identiﬁed a number of 3- and
4-node motifs that were consistent with expression values
(Figure3).Wethusidentiﬁed39genesinvolvedin55switches
forming a single cluster, which we call the ‘core’ network
(Figure 4).
Computation of the stability of the core network cluster
revealstwoattractors,inwhichallgenesareeitherinanONor
an OFF state, which exactly match the expression pattern.
The two most commonly found motifs are positive forward
loop motifs with OFF/OFF/OFF changed to the ON/ON/ON
states during the course of the disease.
Consistentwiththis,theinsilicoperturbationofsomenodes
of the core cluster trigger a transition from the OFF to the ON
attractor, but the opposite transition (from ON to OFF) is not
triggered by the perturbation of any node in the core. In all, 34
nodes in the cluster are capable of triggering the transition
from OFF to ON when they are perturbed. In contrast, ﬁve
nodes (COL1A1 (collagen type I-a1), COL1A2 (collagen type
I-a2), kruppel-like factor 5 (KLF5), perforin-1 and runt-related
transcription factor 1) constitute a set of genes that potentially
could be in the ON state, taking part in different processes
without leading to the activation of the cluster as a
consequence. We can see in Figure 5 that perturbation of
KLF5, involved in a motif with early growth response 1
(EGR1), does not trigger the transition of the cluster from OFF
to ON (see Supplementary Figure 1 for all perturbation
experiments).
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Cell Death and DiseaseFurthermore, we compared properties of genes in the core
network with remaining genes in the global network (Supple-
mentaryTable1).Speciﬁcityofinter-geneinteractionsmaybe
reﬂected in the network modularity. Using the Newman–
Girvan algorithm, we identiﬁed 11 clusters of which clusters 1
and 2 are mainly occupied by core genes. To identify inter-
cluster connectors, we calculated the participation coefﬁcient
that on average was signiﬁcantly different when comparing
nodes in the core and global networks. The median participa-
tion in the core and global networks was 0.45 and 0,
respectively; the distributions in the two groups differed
signiﬁcantly (Mann–Whitney–Wilcoxon W¼2272, n1¼44,
n2¼191, P-value¼1.66e-07).
The betweenness centrality of a gene is a centrality
measure that is proportional to the number of shortest paths
between genes in the network that go through the gene in
question. High betweenness centrality corresponds to high
level of inter-node communication, and is therefore an
appropriate measure for highlighting which genes link
different molecular processes and pathways. Median be-
tweenness centrality in the core and global networks are 243
and 0, respectively; the distributions in the two groups differ
signiﬁcantly (Mann–Whitney–Wilcoxon W¼1430, n1¼44,
n2¼191, P-value¼3.65e-14). We identiﬁed a group of
genes, which act as potential hubs and exist in the core
network (having a betweenness centrality score Z0.10 in the
core network, as well as Z2900 in the global network, being
the top four ranking genes in both cases).
The genes with the highest betweenness centrality were
HIF1A (hypoxia-inducible factor 1a-subunit), EGR1, STAT1
(signal transducers and activators of transcription 1) and
CXCL12(chemokine(C–X–Cmotif)ligand12)andtheyareall
overexpressed in the case of phosphorylated PPARg (the
putative disease state). We examined these genes in more
detail with regard to their association with adipogenesis, for
which PPARg is the master regulator under any condition, to
conﬁrm that our core network is consistent with experimental
studies.Wefoundthatthiswasindeedthecase:theroleofthe
transcription factor HIF1A in adipocyte differentiation has
been described previously,
23 EGR1 functions as a transcrip-
tional regulator the expression of which is rapidly induced
during the differentiation of murine 3T3-L1 adipocytes,
24
STAT1 also acts as a transcription activator, which is rapidly
activated in the 3T3-L1 adipocyte cell culture model,
25 and
CXCL12 is a chemokine, which demonstrates a signiﬁcant
increase in expression in differentiating 3T3-L1 preadipo-
cytes.
26
Discussion
The metabolic syndrome is a common disease and is
associated with increased incidence of type II diabetes
Figure 2 Structural analysis of the disease-related form of PPARg (phosphorylated) in comparison with healthy state (non-phosphorylated). (a) PPARg–RXRa dimer
crystal structure; the LBD of PPARg (green) interacts with the DBD of RXRa (light blue). Phosphorylated serine 273 DNA perturbs the LBD–DBD interface changing the zinc-
ﬁnger helix (red) interaction with DNA (orange); zinc ions are shown as purple spheres. (b) The DBD of RXRa. RMSD was calculated for each tenth frame of the molecular
dynamics trajectory. Phosphorylation leads to a moderate but stable changein elevatedmean deviation of DBD structure atoms. (c) The DBD of RXRa. Time-averaged RMS
ﬂuctuations for phosphorylated wild-type and non-phosphorylated mutant S273A wild-type PPARg. The black bar highlights the highest differencein stability, which is located
in the zinc-ﬁnger helix. (d) The LBD of PPARg. Similar proﬁles of RMSF for both wild-type and mutant structures indicating that phosphorylation does not reduce the stability
of the LBD
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Cell Death and Diseasemellitus and cardiovascular mortality. Its treatment is de-
signed to target the different components of the syndrome
(such as high triglyceride, cholesterol and glucose levels and
high blood pressure). Causally, the metabolic syndrome is
linked to obesity-related insulin resistance.
27 Thus, the
discovery of PPARg as a master regulator of adipogenesis,
the decreased activity of which was also shown to be linked to
insulin resistance,
28,29 was very important. It was assumed
that increasing PPARg activity would potentially represent a
unifying strategy to target the metabolic syndrome as an
entity. Unfortunately, unwanted side effects such as weight
gain, heart failure and even osteoporosis, as well as
discrepant results between genetic and pharmacological
modulations of PPARg, outbalance the observed clinical
beneﬁts, which mostly rely on improved blood sugar control
and lipid metabolism.
30
PPARg still represents a desirable drug target, but research
over the last decade showed that its biological function with
regard to adipogenesis is a balanced and thrifty response.
31
Aspects such as co-factor recruitment and function and/or
post-translational modiﬁcations have to be taken into con-
sideration, before more speciﬁc/distinct new approaches to
modify PPARg action can lead to new compounds.
PPARg expression is also inﬂuenced by GATA-binding
protein 2 (GATA2), a transcription factor speciﬁcally ex-
pressed in the stromal vascular fraction of the adipose tissue,
which is also where preadipocytes are located. The transition
from preadipocyte to adipocyte is blocked, at least in part, by
GATA2’s suppression of PPARg; insulin has downstream
effects on the kinase v-akt murine thymoma viral oncogene
homolog 1 (Akt) which phosphorylates GATA2, impairing
GATA2’s translocation to the nucleus, leading to a reduced
suppression of PPARg in the nucleus, thus promoting
adipogenesis. In the insulin-resistant state, the phosphoryla-
tion of GATA2 by Akt is disturbed and consequently
adipogenesis regulation is dysregulated. PPARg-driven adi-
pogenesis is reduced, whereas the remaining preadipocytes
start expressing pro-inﬂammatory cytokines, an observation
contributingtotheunderstandingofthepuzzlingphenomenon
of improved metabolic outcome of adipogenesis-promoting
PPARg agonists. GATA2 was not among the DEGs in our
study, but this is not unexpected as GATA2’s activity is
regulated through phosphorylation.
32
Metalloproteinase inhibitor 3 (TIMP3) isa member of our core
network and was originally linked to Sorsby’s fundus dystrophy,
which is an autosomal dominant macular degeneration
disorder. This gene has been linked to a number of other
diseases including, more recently, the metabolic syndrome, in
particular with insulin resistance, hepatic inﬂammation, dyslipi-
demia and atherosclerosis in diabetic subjects.
33,34 Ap o s s i b l e
mechanism of how PPARg and TIMP3 are connected may be
that TIMP3 expression inﬂuences C/EBPb (CCAAT/enhancer-
binding protein beta) expression, which in turn induces C/EBPa
(CCAAT/enhancer-binding protein alpha) and PPARg during
adipocyte differentiation.
35
Post-translational modiﬁcation can be seen as perturba-
tionsoftheenvironmentinwhichaproteinexists.Theeffectof
such a post-translational modiﬁcation on a protein is a good
situation to examine the hypothesis of the population shift of
molecules, which proposes that the external stimuli stabilize
and therefore populate pre-existing, although previously non-
overrepresented molecule states. In biological terms, a
population of protein conformers may be shifted towards
malfunctioning, diseased-related conformation(s), that is, the
sustainedperturbationofproteinstructureisapotentialtrigger
for changes of molecular networks associated with speciﬁc
disease phenotypes.
Choietal.
20studiedtheroleofPPARginthecontextofpost-
translational modiﬁcation, that is, the phosphorylation of
serine 273 in the LBD of PPARg; a number of genes were
identiﬁed the differential expression of which is caused by a
change in the conformation of the PPARg–RXRa dimer when
serine 273 is phosphorylated. This modiﬁcation was shown to
inﬂuence gene expression of disease (obesity, insulin
resistance)-relevant genes independently from the general
receptor transcriptional activity.
11
Figure 3 Bi-stable motifs with matching gene expression values: n is the
number of motifs of a given type found in the core network. A1 is attractor state 1,
and A2 is attractor state 2
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Cell Death and DiseaseTo study the effects of perturbation on a structural level, we
performed a MD simulation to examine the impact of
phosphorylation on the PPARg–RXRa dimer, demonstrating
that phosphorylated PPARg destabilizes the PPARg–RXRa
dimer, which may be a mechanism explaining the altered
transcriptional regulation of PPARg target genes. Interest-
ingly, phosphorylation at another residue (Ser112) modulates
PPARg activity with positive effects on glucose and lipid
Figure 4 The core network. (a) This network consists of 39 nodes and 55 bi-stable motifs. (b) Example of bi-stable switch motif, existing in ON/ON/ON or OFF/OFF/OFF
states
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Cell Death and Diseasemetabolism in vivo possibly by decreasing its afﬁnity for
endogenous ligands.
36 This ﬁnding corresponds well to our
ﬁnding of a destabilized PPARg–RXRa dimer.
Furthermore, we analyzed perturbations of biological net-
works associated with changes in PPARg, by examining the
DEGs comparing wild-type phosphorylated PPARg with
mutant non-phosphorylated PPARg. A network was con-
structed connecting these DEGs using the biomedical
literature-basedResNetmammaliandatabase.Thisdatabase
only includes interactions previously reported in humans,
mouse or rat. Therefore, it can be expected that there will be
little bias introduced by orthologs from exotic species, that is,
species distant to mouse in the phylogenetic tree.
We found an enrichment of bi-stable switches in wild-type
phosphorylated state containing genes that signiﬁcantly
change their expression levels in an adipogenesis-dependent
manner. Of particular interest were the genes with the highest
betweenness centrality: HIF1A, EGR1, STAT1 and CXCL12.
These genes are all overexpressed in the putative disease
state and all have been previously described to have a role in
adipogenesis.
23–26 Betweenness centrality is a measure of
the inﬂuence that a node has over the spread of the
information through the network,
37 and our ﬁnding that the
hub genes with the highest levels of betweenness centrality
consist of three transcriptional regulators and one chemokine
isconsistentwiththemfunctioningasinformationpropagators
in the network.
The bi-stable motifs we identiﬁed assemble an intercon-
nected core network of genes, which have two steady-stable
states corresponding to gene functionality states. This stable
core network gives robustness to the cellular network by
keeping the system in the non-phosphorylated putative
healthy state; however, once the system is pulled out of this
state, it stabilizes the network in a phosphorylated putative
disease-related state.
Materials and Methods
Molecular modeling. The therapeutic ligand present in the intact structure of
the PPARg–RXRa–DNA complex (PDB ID: 3DZY)
21 was replaced with
docosahexanoic acid, which is a natural ligand of PPARg. MD simulations were
performed with Gromacs
38 and served as a tool to generate perturbed states of
proteins.ImplicitsolventgeneralizedbornsimulationswiththeAmber99sb-ildnforce
ﬁeld were carried out for wild-type and mutant proteins: energy minimizations were
performed and the production runs were 50ns in length.
Network analysis. For our analysis, we extracted DEGs from the results of
gene expression analysis experiments by Choi et al.,
20 in which PPARg-null mouse
embryonic ﬁbroblasts were transfected with wild-type PPARg (phosphorylated) or
the S273A PPARg mutant (not phosphorylated). The cutoffs for selecting the DEGs
were uncorrected P-values r0.008 and corrected false discovery rate P-values
r0.15. This resulted in 577 DEGs, which we used in our subsequent analysis.
Subsequently, the ResNet mammalian database from Ariadne Genomics (http://
www.ariadnegenomics.com/) was used to construct an interaction network of 235
DEGs with directed interactions (the ‘global’ network). This database includes
biological relationships and associations, which have been extracted from the
biomedical literature using Ariadne’s MedScan technology. MedScan processes
sentences from PubMed abstracts and produces a set of regularized logical
structures representing the meaning of each sentence. The ResNet mammalian
databasestoresinformationharvestedfromtheentirePubMed,includingmorethan
715000 relations for 106139 proteins, 1220 small molecules, 2175 cellular
processes and 3930 diseases. The focus of this database is solely humans, mouse
and rat.
Motif detection was performed using the FANMOD algorithm
39 for the global
network and limited to motifs consisting of 2, 3, 4 or 5 nodes each. Each resultant
topology was analyzed in comparison with 1000 separately randomized versions of
the initial network. Using both the original and the randomized versions, z-scores
and P-values could be calculated for all motifs discovered in the original network.
The z-score of a motif is the original frequency minus the random frequency divided
by S.D. The P-value of a motif is the number of random networks in which it
occurred more often than in the original network, divided by the total number of
randomnetworks.Ofthebi-stableswitchmotifswe identiﬁed,we alsoexaminedthe
expression proﬁle of the genes in each motif to ensure that the expression proﬁle
was consistent in all motif members. We constructed a network (the ‘core’ network)
consisting of 39 DEGs that occur in bi-stable motifs, which are signiﬁcantly
overrepresentedintheglobalnetworkandthegenesofwhichareinthestablestate,
matching the experimental expression values.
To compute the attractors of the core network, we used the program SQUAD
(www.enﬁn.org).
40 The program converts the network into a continuous dynamical
system based on ordinary differential equations. In the absence of detailed kinetic
parameters, the program interpolates a sigmoid curve between the states
completely ON and completely OFF for each node. SQUAD ﬁrst calculates the
steady states found in a discrete dynamical system (Boolean model) and then uses
these states as a guide to localize the steady states in the continuous model.
Perturbations were also simulated using SQUAD. Each perturbation is a single
pulse that changes the state of the node from 0 to 1 in the OFF attractor or from
1 to 0 in the ON attractor as initial states of the system.
The DEGs of the core and global networks were divided into groups by
topological modularization using the Newman–Girvan algorithm. Participation (P) of
a node in intra-modular communication is calculated as follows:
Pi ¼ 1  
X NM
s¼1
K i
S
ki
   2
where NM¼number of modules, Ks¼number of connections with module s,
ki¼total degree of module k. Analysis of betweenness centrality was calculated
with igraph library in R comparing the core and global networks. The participation
coefﬁcient and betweenness centrality results for the core and global network
groups were compared with the Mann–Whitney–Wilcoxon test to check the
statistical signiﬁcance of the differences.
We also examined these genes in more detail with regard to their association
with adipogenesis, for which PPARg is the master regulator under any condition, to
conﬁrm that our core network is consistent with experimental studies.
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